Alphamab Oncology - ESG Rating & Company Profile powered by AI
The page is a free ESG report covering Alphamab Oncology. This assessment of Alphamab Oncology was assembled by All Street Sevva using proprietary Cognitive Robots. Other companies in the rating industry group for Alphamab Oncology are displayed below.
Alphamab Oncology in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.9; made up of an environmental score of 4.6, social score of 6.0 and governance score of 4.0.
4.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1047 | SQZ Biotechnologies Co | 5.0 | High |
| 1047 | Zenabis Global Inc | 5.0 | High |
| 1082 | Alphamab Oncology | 4.9 | High |
| 1082 | AngioLab Inc | 4.9 | High |
| 1082 | Annexon Inc | 4.9 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Alphamab Oncology have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Alphamab Oncology disclose current and historical energy intensity?
Sign up for free to unlockDoes Alphamab Oncology report the average age of the workforce?
Sign up for free to unlockDoes Alphamab Oncology reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Alphamab Oncology disclose its ethnicity pay gap?
Sign up for free to unlockDoes Alphamab Oncology disclose cybersecurity risks?
Sign up for free to unlockDoes Alphamab Oncology offer flexible work?
Sign up for free to unlockDoes Alphamab Oncology have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Alphamab Oncology disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Alphamab Oncology conduct supply chain audits?
Sign up for free to unlockDoes Alphamab Oncology disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Alphamab Oncology conduct 360 degree staff reviews?
Sign up for free to unlockDoes Alphamab Oncology disclose the individual responsible for D&I?
Sign up for free to unlockDoes Alphamab Oncology disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Alphamab Oncology disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Alphamab Oncology disclose water use targets?
Sign up for free to unlockDoes Alphamab Oncology have careers partnerships with academic institutions?
Sign up for free to unlockDid Alphamab Oncology have a product recall in the last two years?
Sign up for free to unlockDoes Alphamab Oncology disclose incidents of discrimination?
Sign up for free to unlockDoes Alphamab Oncology allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Alphamab Oncology issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Alphamab Oncology disclose parental leave metrics?
Sign up for free to unlockDoes Alphamab Oncology disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Alphamab Oncology disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Alphamab Oncology disclose the pay ratio of women to men?
Sign up for free to unlockDoes Alphamab Oncology support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Alphamab Oncology disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Alphamab Oncology reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Alphamab Oncology involved in embryonic stem cell research?
Sign up for free to unlockDoes Alphamab Oncology disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Alphamab Oncology disclose its waste policy?
Sign up for free to unlockDoes Alphamab Oncology report according to TCFD requirements?
Sign up for free to unlockDoes Alphamab Oncology disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Alphamab Oncology disclose energy use targets?
Sign up for free to unlockDoes Alphamab Oncology disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Alphamab Oncology have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Alphamab Oncology
These potential risks are based on the size, segment and geographies of the company.
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.